Unity Biotechnology Inc (NASDAQ: UBX) has announced positive data from its Phase 1 safety study of UBX1325 in patients with diabetic macular edema (DME) and wet age-related macular degeneration (wet ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback